Tesamorelin 10mg
Tesamorelin 10mg — for in vitro laboratory research use only.
Product Overview
Tesamorelin is a pharmaceutical-grade research compound supplied as a lyophilized powder. Each batch undergoes independent third-party testing with a Certificate of Analysis (COA) available on request.
Specifications
| CAS Number | 218949-48-5 |
| Molecular Formula | C221H366N72O67S |
| Molar Weight | ~5135.86 g/mol |
| Sequence | 44-amino-acid GHRH(1-44) analog, N-terminally modified with a trans-3-hexenoyl group |
| Classification | Synthetic growth-hormone-releasing hormone (GHRH) analog |
| Appearance | White to off-white lyophilised powder (typical presentation) |
| Solubility | Soluble in sterile water or bacteriostatic water |
| Storage | Store lyophilised powder desiccated and protected from light at -20°C. Once reconstituted, store at 2-8°C for short-term use and avoid repeated freeze-thaw cycles. |
| Shelf Life | Typically stable for up to 24 months when stored lyophilised, desiccated, and protected from light at -20°C — confirm against the specific batch's Certificate of Analysis. |
Description & Mechanism of Action
Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH), modified with a stabilising N-terminal group to extend its half-life relative to the natural hormone. It binds GHRH receptors on pituitary somatotroph cells with high affinity, stimulating the pulsatile release of endogenous growth hormone (GH) in a pattern consistent with the body's natural secretion rhythm, preserving normal negative-feedback regulation via rising IGF-1 and somatostatin tone. Released GH stimulates hepatic IGF-1 production, which mediates downstream effects including lipolysis — particularly in visceral adipose tissue, which carries a higher density of GH receptors than subcutaneous fat — along with protein anabolism in skeletal muscle and modulation of glucose metabolism. Tesamorelin (brand name Egrifta) holds FDA approval for the treatment of HIV-associated lipodystrophy, and the visceral-fat reduction data referenced in the research literature reflects the clinical trials supporting that approved indication.
Applications in Research
- Studying GHRH-receptor-mediated pituitary signalling
- Investigating the GH/IGF-1 axis and its downstream metabolic effects
- Visceral adipose tissue and body-composition research models
- Reference compound in growth-hormone secretagogue comparison studies
Handling, Reconstitution & Stability
- Handle as a hygroscopic powder; open vials and weigh under dry conditions where possible
- Reconstitute with sterile water or bacteriostatic water, adding solvent slowly down the side of the vial
- Swirl gently to dissolve — avoid vigorous shaking
- Filter-sterilise (e.g. 0.22 µm) immediately before use if required by your protocol
- Aliquot reconstituted solution and store at -20°C or below; avoid repeated freeze-thaw cycles
Precautions & Notes
- Tesamorelin holds FDA approval for a specific clinical indication (HIV-associated lipodystrophy, brand name Egrifta); research use should not be conflated with that approved medical use
- Experimental effects are concentration-, duration-, and model-dependent
- Include appropriate experimental controls to distinguish specific from non-specific effects
- For laboratory research use only — not for human or veterinary use outside of an approved medical context
This product is supplied for in vitro research purposes only. It is not intended for human or animal administration, diagnostic use, or any other purpose. Handle in accordance with good laboratory practice guidelines.